Mesa Laboratories, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2014, filed June 4, 2014. The request metadata references “2012 Q4,” but the supplied filing is the 2014 annual report and includes comparative fiscal years 2013 and 2012.
Business context
Mesa manufactures and services quality-control products sold primarily into regulated niche markets. Its three divisions are Biological Indicators, Instruments, and Continuous Monitoring. Products and services support healthcare, pharmaceutical, medical device, food and beverage, industrial hygiene, and laboratory customers. Approximately 56% of sales were to U.S. customers and 44% to foreign customers in fiscal 2014.
Revenue is generated from product sales and services. Biological indicator products are recurring consumables and generally less economically sensitive, while instruments and continuous monitoring systems involve more discretionary capital spending. The company had 273 employees at March 31, 2014.
Financial performance and liquidity
| Metric | FY2014 | FY2013 | Change |
|---|---|---|---|
| Revenue | $52.724 million | $46.435 million | +14% |
| Gross profit | $31.688 million | $28.862 million | +10% |
| Gross margin | 60% | 62% | Down 2 percentage points |
| Operating income | $11.785 million | $13.104 million | −10% |
| Net income | $9.000 million | $8.450 million | +7% |
| Net margin | 17% | 18% | Down 1 percentage point |
| Diluted EPS | $2.49 | $2.35 | +6% |
| Adjusted net income | $11.046 million | $10.144 million | +9% |
Biological Indicators revenue increased 7% to $22.992 million, Instruments revenue increased 6% to $26.389 million, and Continuous Monitoring contributed $3.343 million following the Amega and TempSys acquisitions. Services represented $8.185 million of total revenue, up from $5.845 million.
Operating expenses rose 26% to $19.903 million. Selling expense increased 32%, general and administrative expense increased 26%, and research and development expense increased 15% to $2.320 million. General and administrative expense included a $1.408 million accrual for potential state sales-tax liabilities.
Net cash provided by operating activities was $12.373 million, compared with $11.402 million in fiscal 2013. Investing cash use was $23.138 million, primarily for acquisitions, and financing cash provided was $12.334 million, reflecting debt borrowings, option exercises, debt repayments, and dividends. Capital expenditures were $1.041 million.
At March 31, 2014, cash and cash equivalents were $5.575 million and working capital was $16.351 million. Total assets were $97.529 million, including $37.866 million of goodwill and $25.417 million of net intangible assets. Long-term debt was $16.500 million, compared with $4.000 million at March 31, 2013.
The company paid $1.989 million in dividends during fiscal 2014. Quarterly dividends increased from $0.13 per share in fiscal 2012 to $0.14 and then $0.15 per share in fiscal 2014.
Material changes versus the prior comparable period
- Revenue grew 14%, but gross margin declined from 62% to 60% and operating income declined 10%, primarily because of acquisition-related costs, integration activity, higher selling expenses, and increased administrative costs.
- A third reporting segment, Continuous Monitoring, was created after the November 2013 acquisitions of Amega Scientific and TempSys. These acquisitions generated $3.343 million of fiscal 2014 revenue but were negatively affected by integration activities.
- Mesa acquired the SureTorque product line in July 2013 and disposed of the NuSonics product line in August 2013, recognizing a $468,000 pretax gain on the disposal.
- The company revised its estimated Bios contingent consideration liability from $2.140 million to $1.120 million, producing a $1.020 million gain included in other income.
- Goodwill increased from $23.640 million to $37.866 million, and net intangible assets increased from $15.418 million to $25.417 million, primarily because of acquisitions.
- Inventory increased to $7.771 million from $5.576 million, partly reflecting acquired operations and inventory purchases.
- Research and development spending increased to $2.320 million from $2.011 million.
Guidance, outlook, risks, and unusual items
Management did not provide formal revenue or earnings guidance. Management stated that Biological Indicators markets remained strong and that demand for Instruments and newly acquired Continuous Monitoring products was also strong, although economic uncertainty continued to delay discretionary capital purchases. Management expected integration of Amega and TempSys to be substantially completed by the beginning of the second half of fiscal 2015, with improved revenue and margins thereafter. New products were expected from the Biological Indicators and Instruments divisions during the following year.
In April 2014, the credit facility was amended to add a $15.000 million term loan and extend maturity to June 30, 2017. The term loan bears interest at LIBOR plus 2% and requires quarterly principal payments beginning July 15, 2014. As of May 31, 2014, outstanding indebtedness was $27.000 million, with $8.000 million of unused capacity. The facility is secured by company assets and includes leverage and fixed-charge coverage covenants; Mesa reported compliance at March 31, 2014.
- Variable-rate debt exposes the company to higher interest expense; management estimated that a one-percentage-point rate increase would raise annual interest expense by approximately $74,000 based on fiscal 2014 debt levels.
- Potential Amega contingent consideration ranges from zero to $10.000 million and is payable in fiscal 2017; $500,000 was accrued at year-end.
- Potential Bios contingent consideration ranges from zero to $6.710 million; $1.120 million remained accrued and is payable in fiscal 2016.
- State sales-tax exposure was estimated at approximately $1.5 million, including the $1.408 million fiscal 2014 accrual. The ultimate liability could change based on audits, exemptions, prior collections, exposure periods, penalties, and interest.
- Acquisition integration, goodwill and intangible-asset impairment, regulatory compliance, product liability, competition, economic conditions, supply-chain disruptions, and customer capital-spending decisions are material risks.
- The company planned to implement another ERP system over the subsequent 10 to 16 months, which could require significant cash expenditures.
Auditors issued an unqualified opinion on the consolidated financial statements and internal control over financial reporting. The TempSys acquisition was excluded from management’s internal-control assessment because of its timing; TempSys represented approximately 16% of total assets and 3% of fiscal 2014 net sales.
Most important facts to verify
- Confirm the intended period: the supplied filing is FY2014, not 2012 Q4.
- Assess whether Continuous Monitoring integration achieved the expected fiscal 2015 revenue and margin improvement.
- Reconcile post-year-end debt, term-loan payments, covenant compliance, and available borrowing capacity.
- Monitor final Amega and Bios contingent consideration payments against recorded liabilities.
- Evaluate changes in the estimated state sales-tax exposure and any related penalties or interest.
- Review goodwill and intangible-asset carrying values, particularly after the acquisitions and integration activities.
- Separate recurring operating performance from the $1.020 million Bios estimate gain and $468,000 NuSonics disposal gain.